Arabic Arabic English English French French German German

Effect of ginsenoside-Rg1 on experimental Parkinson’s disease.


Exp Ther Med. 2021 Jun ;21(6):552. Epub 2021 Mar 25. PMID: 33850524

Abstract Title: 

Effect of ginsenoside-Rg1 on experimental Parkinson’s disease: A systematic review and meta-analysis of animal studies.


Previous studies have reported that ginsenoside-Rg1 (G-Rg1) was able to mitigate the loss of dopaminergic neurons in animal models of Parkinson’s disease (PD). The present study provided a systematic review and meta-analysis of preclinical studies to pool current evidence on the effect of G-Rg1 on neurogenesis in the treatment of PD. Eligible studies were identified through a search from six databases: PubMed, EMBASE, Web of Science, VIP, Chinese National Knowledge Infrastructure and the Wanfang database. Primary outcomes were tyrosine hydroxylase (TH)-positive cells in the nigra, Nissl staining-positive cells in the nigra, pole test time and dopamine (DA) levels in the striatum. A total of 18 eligible studies were identified, involving 343 animals. Of these, 13 reported a significant relationship between G-Rg1 and improved TH-positive cells in the nigra compared with the control group (P

read more

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

A new ketogenic formulation improves functional outcome and reduces tissue loss following traumatic brain injury.

Next Post

Ginseng polysaccharide could effectively prevent cisplatin-induced ER stress, inflammation, and apoptosis in renal cells.

Related Posts